Pharma BD Deal Intelligence
FDA approval was won, but the product it paid for was pulled from the market within three years of launch and never generated meaningful revenue.
Full analysis, sources & comparables →Allergan to acquire Oculeve's dry eye disease development programs; reports the $125 million upfront and milestone structure for the OD-01 neurostimulation…
Allergan acquires Oculeve, adding the dry eye disease device pipeline to its eye care franchise; factual coverage of the completed transaction.
Analyst characterization of the Oculeve integration as a model 'hands-off' acquisition; Allergan CEO Brent Saunders quoted leaving the team 'exactly where they…
Source summaries from our enrichment pipeline; follow links for originals.
All 8 sources with sentiment breakdown →
Allergan acquired Oculeve for $125M upfront plus commercialization milestones for OD-01, a non-invasive intranasal neurostimulation device for dry eye disease, plus an earlier-stage dry eye device program. Closed August 10, 2015. Borderline by value threshold but strategically notable for eye care franchise.
FDA approval was won, but the product it paid for was pulled from the market within three years of launch and never generated meaningful revenue.
Assessment window: 10yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Allergan plc / Oculeve, Inc. (this deal) | 2015 | $250M | 33 |
| Allergan plc / Merck & Co., Inc. (CGRP receptor antagonist program) | 2015 | $250M | 91 |
| Allergan plc / SkinMedica, Inc. | 2012 | $375M | 55 |
| Allergan plc / Inamed Corporation | 2005 | $3.2B | 50 |
| Allergan plc / Zeltiq Aesthetics, Inc. | 2017 | $2.5B | 32 |
| Allergan plc / Kythera Biopharmaceuticals, Inc. | 2015 | $2.1B | 23 |
| Allergan plc / Anterios, Inc. | 2016 | $90M | 19 |
← Browse all deals · How we score deals
More: 2015 deals · Allergan plc deals · Ophthalmology deals